U.S. News
Senate Urged to Probe Abortion Pill Safety Moves
Clear Facts
- The Restoration of America Foundation has called on the Senate Finance Committee to question HHS Secretary Robert F. Kennedy Jr. about the removal of safety protocols for the abortion pill mifepristone.
- The group argues that the Biden administration’s rollback of longstanding safeguards enables online prescribing and mail delivery, exposing women to increased risks.
- ROAF cites a recent investigation showing nearly 11 percent of chemical abortions led to serious complications, exceeding prior FDA claims.
The Restoration of America Foundation is urging senators to demand answers on why the FDA’s safety protocols for mifepristone were eliminated. The group raises concerns that these changes put women’s health at risk and may shift costs to taxpayers.
The foundation highlights that abortion pills can now be prescribed via telehealth and sent by mail, removing in-person screening for complications. ROAF maintains these protections were in place for over twenty years before the recent Biden-era rollback.
“The removal of key Risk Evaluation and Mitigation Strategy (REMS) requirements for mifepristone has eliminated essential safeguards that protected women’s health for over two decades,” said Doug Truax, founder and CEO of the Restoration of America Foundation.
He stated, “We urge the Senate to demand clear answers about why these safety protocols were removed and when they will be reinstated.” Truax also warned that allowing abortion drugs to be ordered and delivered without medical screening “puts women at serious risk.”
He added, “Women deserve to know about potential complications and have immediate access to emergency care if needed.”
Recent reports referenced by ROAF indicate that complications from chemical abortions may be significantly underreported. One investigation cited found complication rates far higher than the FDA’s previous figures, raising questions about transparency and oversight.
During the upcoming Senate hearing, these concerns are expected to be discussed, focusing on the need for safety and accountability regarding abortion drugs.
HHS spokeswoman Emily G. Hilliard said, “Commissioner Makary will ensure gold standard science is used while incorporating practical, common-sense considerations to its regulatory processes.”
Stay alert for outcomes from this Senate hearing and ongoing discussions about abortion pill safety and accountability. To read the full story, visit the source below.
Let us know what you think, please share your thoughts in the comments below.
